Patients with rheumatoid arthritis (RA) have longer persistence with upadacitinib than tumor necrosis factor inhibitors (TNFi), according to a study published online June 23 in Rheumatology.
4 hours ago
0
0
The American Gastroenterological Association (AGA) has released a comprehensively updated clinical guideline on the pharmacological management of moderate-to-severe Crohn's disease. The new guideline uses cutting-edge network ...
Nov 20, 2025
0
30
A common medication already used for autoimmune diseases such as rheumatoid arthritis is effective for patients with giant cell arteritis, according to findings from a team at the Perelman School of Medicine at the University ...
Jun 25, 2025
0
16
For patients with ulcerative colitis, upadacitinib is associated with improved disease-specific outcomes at 12 months compared with tofacitinib, according to a study published in the December issue of the American Journal ...
Dec 23, 2024
0
18
Long-term treatment of adolescents with moderate-to-severe atopic dermatitis (AD) with upadacitinib is safe and effective through 76 weeks, according to a study published online Oct. 23 in JAMA Dermatology.
Oct 26, 2024
0
19
The U.S. Food and Drug Administration has expanded indications for AbbVie's Rinvoq (upadacitinib) to now include pediatric patients (ages 2 years and older) with polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic ...
Jun 24, 2024
0
55
Newer oral medications for rheumatoid arthritis (RA) do work quite well in the "real world," despite some doubts that they would, according to a new study.
Nov 4, 2023
0
313
According to a new paper in Rheumatology, published by Oxford University Press, JAK inhibitors, which doctors have used to treat patients with arthritis despite concerns about the effectiveness of such drugs, actually do ...
Nov 1, 2023
0
70
For patients with inflammatory bowel disease (IBD), monitoring by intestinal ultrasound (IUS) results in reduced time to treatment change and to remission, according to a study presented at the annual meeting of the American ...
Oct 25, 2023
0
47
For patients with moderate-to-severe Crohn disease, upadacitinib induction and maintenance treatment are superior to placebo, according to a study published in the May 25 issue of the New England Journal of Medicine.
May 31, 2023
0
33
